Edwards Lifesciences Corporation (EW) VP Donald E. Bobo, Jr. Sells 5,300 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total value of $594,395.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, August 4th, Donald E. Bobo, Jr. sold 25,000 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00.
  • On Friday, July 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $114.68, for a total value of $607,804.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $117.15, for a total value of $656,040.00.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded up 1.79% during mid-day trading on Friday, hitting $113.50. The stock had a trading volume of 1,944,139 shares. The company has a market cap of $23.97 billion, a PE ratio of 34.43 and a beta of 0.64. The stock has a 50 day moving average price of $113.99 and a 200-day moving average price of $108.88. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. During the same period last year, the business posted $0.76 EPS. Edwards Lifesciences Corporation’s quarterly revenue was up 10.9% on a year-over-year basis. On average, equities analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) VP Donald E. Bobo, Jr. Sells 5,300 Shares” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/09/17/edwards-lifesciences-corporation-ew-vp-sells-594395-00-in-stock.html.

Several brokerages have weighed in on EW. Canaccord Genuity reissued a “buy” rating and issued a $155.00 price target (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. BidaskClub cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Zacks Investment Research cut Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, June 8th. Jefferies Group LLC restated a “buy” rating and issued a $115.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $120.75.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lord Abbett & CO. LLC increased its stake in Edwards Lifesciences Corporation by 58.4% in the 2nd quarter. Lord Abbett & CO. LLC now owns 83,718 shares of the medical research company’s stock valued at $9,899,000 after purchasing an additional 30,875 shares in the last quarter. Toronto Dominion Bank increased its stake in Edwards Lifesciences Corporation by 24.0% in the 2nd quarter. Toronto Dominion Bank now owns 71,106 shares of the medical research company’s stock valued at $8,406,000 after purchasing an additional 13,747 shares in the last quarter. Advisory Services Network LLC increased its stake in Edwards Lifesciences Corporation by 0.9% in the 2nd quarter. Advisory Services Network LLC now owns 12,565 shares of the medical research company’s stock valued at $1,486,000 after purchasing an additional 112 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in Edwards Lifesciences Corporation by 14.2% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 361,650 shares of the medical research company’s stock valued at $42,761,000 after purchasing an additional 44,877 shares in the last quarter. Finally, Covington Capital Management increased its stake in Edwards Lifesciences Corporation by 28.7% in the 2nd quarter. Covington Capital Management now owns 9,983 shares of the medical research company’s stock valued at $1,180,000 after purchasing an additional 2,225 shares in the last quarter. 82.36% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply